P atients with advanced Hodgkin disease (HD) who have a relapse after first-line chemotherapy can achieve further remissions with high-dose chemotherapy and transplantation of hematopoietic stem cells. Unfortunately, relapse or disease progression after autologous transplant occurs in a significant proportion of cases, and no clear treatment guidelines exist for these patients. We report the case of a patient with a refractory localized HD who had a sustained long-term remission (39 months) after surgery alone.
Clinical Summary
A 22-year-old male student was seen in November 1995 with B signs and superior vena cava syndrome. HD of the nodular sclerosis type was diagnosed at stage IIIB with bulky mediastinum. The patient was treated with 6 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine to achieve a complete remission, consolidated by 40-Gy radiotherapy to initial sites of bulky mediastinum and by 30-Gy radiotherapy to neck and axillary areas. Two years after completion of therapy, the disease recurred as a localized left lung suprahilar nodule within the previously irradiated field. The patient was successfully treated with 3 courses of etoposide, vinblastine, cytarabine, and cisplatin chemotherapy, followed by high-dose chemotherapy (carmustine, etoposide, cytarabine, and melphalan) and autologous hematopoietic stem cell transplantation in December 1998. The disease recurred at the same location in November 1999. The patient was treated with 4 cycles of standard bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone therapy, with complete remission. However, this discrete lesion reappeared in 
Discussion
Patients with advanced HD that relapses after first-line chemotherapy may have further remissions with salvage treatment. Highdose chemotherapy and transplantation of hematopoietic stem cells improves freedom from treatment failure in patients with chemosensitive first relapse of HD, irrespective of delay after initial remission. [1] [2] [3] Unfortunately, relapse or disease progression after autologous transplantation occurs in a significant proportion of patients with HD, and no clear-cut therapeutic guidelines exist for these patients for whom both first-line and high-dose salvage regimens have failed. 4 Gemcitabine, monoclonal antibodies, and active immunotherapy may be tested as alternatives to the option of conventional or nonmyeloablative allogeneic transplantation. 3, 5 The favorable course observed in our patient suggests that elective surgery might be an alternative for highly selected patients with recurrent localized HD, especially pulmonary recurrence.
